ERASMUS MC RESEARCH CODE

Version 1.0

Adoption date: December 2019
PREFACE

LIST OF ABBREVIATIONS

1. SCIENTIFIC RESEARCH INTEGRITY
   1.1 Reading Guide
   1.2 Why have an Erasmus MC Code of Conduct?
   1.3 The scope of the Research Code
   1.4 An ethical science climate
   1.5 Profile of an ethical Erasmus MC researcher
   1.6 Managing within an ethical research and education environment

2. LEGISLATION AND REGULATIONS, THE ERASMUS MC POLICIES AND GUIDELINES
   2.1 General
   2.2 Research with patients or other test subjects
   2.3 Research with human tissue and patient data
   2.4 Research with laboratory animals
   2.5 Research with GMOs and infectious agents
   2.6 Data management
   2.7 Publications
   2.8 Codes of conduct in relationships with third parties
   2.9 Intellectual property

3. References
PREFACE

Acting with integrity must be at the centre of everything we do at Erasmus MC. The Erasmus MC Research Code sets the framework for conducting honest research. It is also the Executive Board’s starting point for continuous dialogue with – and between – researchers and research groups about sound science and its associated dilemmas.

This Research Code is not a law book. Instead, it sets a framework for how we should conduct ourselves in research. The VSNU’s Netherlands Code of Conduct for Research Integrity is taken as the starting point. The Erasmus MC Research Code contains a description of an ethical scientific climate and an overview of relevant laws and regulations at national, European and global levels, supplemented by Erasmus MC-specific information about our policies and guidelines.

The code as presented here (online) is a dynamic document that is tested at least once a year to keep it up-to-date. We amend and supplement it when necessary. The Erasmus MC-specific components are part of our quality assurance system.

The code is aimed at everyone involved in scientific research.

Prof. Dr. Hans van Leeuwen
Dean and member of the Erasmus MC Executive Board
LIST OF ABBREVIATIONS

BROK  Introductory Course in Regulation and Organization for Clinical Researchers (Basiscursus Regelgeving en Organisatie voor Klinische onderzoekers)
BSO   Biological Safety Officer
CCD   Central Animal Testing Committee (Centrale Commissie Dierproeven)
CCMO  Central Committee on Research Involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek)
CGR   Code for Pharmaceutical Advertising (Code Geneesmiddelen Reclame)
CIOMS Council for International Organizations of Medical Sciences
CPO   Consultation Center for Patient-Oriented Research (Consultatiecentrum voor Patiëntgebonden Onderzoek)
DEC   Animal Experiments Committee (Dierexperimentele Commissie)
DMO   Data Management Office
ECB   Erasmus MC Central Biobank
EDC   Experimental Animal Center (Erasmus dierexperimenteel Centrum)
ICMJE International Committee of Medical Journal Editors
IHC   International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
GCP   Good Clinical Practice
GDPR  General Data Protection Regulation
GLP   Good Laboratory Practice
GMP   Good Manufacturing Practice
KNAW  The Royal Netherlands Academy of Arts and Sciences (Koninklijke Nederlandse Akademie van Wetenschappers)
LOWI  National Board for Research Integrity (Landelijk Orgaan voor Wetenschappelijke Integriteit)
METC  Medical Ethical Committee (Medische Ethische Toetsingscommissie)
MVF   Environmental Safety Officer (Milieuveiligheidsfunctionaris)
NFU   The Netherlands Federation of University Medical Centres (Nederlandse Federatie van Universitaire Medische Centra)
NRIN  Netherlands Research Integrity Network
NWO   Dutch Research Council (Nederlandse organisatie voor Wetenschappelijk Onderzoek)
NVWA  Netherlands Food and Consumer Product Safety Authority (Nederlandse Voedsel- en Warenautoriteit)
PKO   Privacy Knowledge Office
PSI   The Parelsoener Institute
TTO   Technology Transfer Office
VSNU  Association of Universities in the Netherlands (Vereniging van Samenwerkende Nederlandse Universiteiten)
WGBO  Medical Treatment Contracts Act (Wet op de Geneeskundige Behandelingsovereenkomst)
WHO   World Health Organization
WMA   World Medical Association
WMO   Medical Treatment Involving Human Subjects Act (Wet medisch wetenschappelijk onderzoek met mensen)
1. **SCIENTIFIC RESEARCH INTEGRITY**

1.1 **Reading Guide**

The Erasmus MC Research Code is primarily a dynamic online document. Its current version can be found on the Erasmus MC website. The code serves as a tool and guide for Erasmus MC employees.

- Chapter 1 contains the most important principles for medical-scientific research in the form of a profile of an honest researcher:
  - We provide a brief overview of the development of the Netherlands Code of Conduct for Research Integrity
  - We describe the core values of an honest Erasmus MC employee
  - We emphasize the importance of integrity management

- Chapter 2 provides an overview of national and international laws and regulations. Material in the blue boxes describes how Erasmus MC helps employees conduct sound scientific research. Additional information can be found through hyperlinks (underlined text).
  - We provide information about various forms of research (such as research with test subjects, body materials or animals)
  - We provide an overview of Erasmus MC policies in areas such as data management, intellectual property, inducements and publishing

- Chapter 3 contains an overview of all relevant links mentioned in this document.

1.2 **Why have an Erasmus MC Code of Conduct?**

The Erasmus MC Board of Directors is responsible for promoting an honest science climate with our available resources. The Research Code plays an important role in this area. All Erasmus MC employees who conduct research within, or on behalf of, the Erasmus MC have the responsibility and the obligation to do so in an ethical manner according to applicable standards. They also have a responsibility to prevent and signal behaviour that does not demonstrate scientific integrity. The code offers researchers a guideline for promoting ethical conduct. To this end, a framework has been developed to indicate how they should act in different situations in accordance with the standards for scientific integrity and applicable laws and regulations. The code also provides a framework for intervention in the event of suspected scientific misconduct.

1.3 **The scope of the Research Code**

This code applies to all persons involved in research within the Erasmus MC. Employees of the Erasmus MC who are involved in scientific research elsewhere in the world, as well as students and fellows who have no employment relationship with the Erasmus MC, are also expected to carry out their research activities in accordance with this code. In addition, the code is intended for third parties, such as clients, sponsors, politicians, social and patient organizations, to acquaint them with the principles used by the Erasmus MC when conducting scientific research.
1.4 An ethical science climate

History
The Memorandum on Scientific Integrity was drawn up in 2001 by the Association of Universities in the Netherlands (VSNU), the Dutch Research Council (NWO) and the Royal Netherlands Academy of Arts and Sciences (KNAW). The memorandum provided a suggestion for procedures that have now been introduced at universities, NWO and KNAW. The memorandum described undesirable scientist behaviour, and introduced the National Board for Research Integrity (LOWI). The LOWI is the central professional body for decentralized complaints procedures in the event of a suspected violation of scientific integrity. Following this memorandum, the VSNU prepared a second document: the Netherlands Code of Conduct for Academic Practice (2004, revision 2012, 2014).

Netherlands Code of Conduct for Research Integrity
In 2018, at the initiative of VSNU, KNAW, NFU, NWO, the TO2 Federation (a collaboration between institutes of applied research) and the Netherlands Association of Universities of Applied Sciences, the Code of Conduct was revised by the Committee for the revision of the Netherlands Code of Conduct for Research Integrity and renamed the Netherlands Code of Conduct for Research Integrity. In this code of conduct, the emphasis is on desired behaviour, focusing on a number of moral qualifications. Five principles are defined: honesty, scrupulousness, transparency, independence and responsibility. It also sets standards for good research practices, followed by duties of care for institutions to create a working environment in which these practices are promoted and guaranteed. The Code of Conduct formulates a number of duties of care for the institutions that subscribe to the code. These include commitment in areas such as training and supervision, research culture, data management, disclosure and dissemination, and ethical standards and procedures. The new Code of Conduct can apply to both public and public-private scientific research in the Netherlands. It also explicitly encompasses cooperation and multidiscipline approaches.

The last part of the new Code of Conduct describes how to deal with potential violations of scientific integrity by using weighting criteria to arrive at a balanced judgment. The Erasmus MC, like all other Dutch universities, endorses this Code of Conduct. The Research Code is an Erasmus MC-specific elaboration and supplement to this Code of Conduct.

More information about Research Integrity can be found on the KNAW website (under the theme Research Integrity), and the website of the Netherlands Research Integrity Network.
1.5 Profile of an ethical Erasmus MC researcher

Honest, careful and transparent
A qualified and competent scientist works carefully and conscientiously when conducting research. The scientific value of research results depends on research originality, as well as on the care taken in design, implementation, data and material management, processing and reporting. The steps of the research process are planned and accurate, and are documented in such a way that the research is reproducible and findings are verifiable and accessible.

Data is handled and stored with integrity, in compliance with the General Data Protection Regulation, and in such a way that it can be viewed by third parties if required. When publishing results, the scientist shows respect for fellow scientists and students through careful acknowledgment of the source, honest mention of everyone who has made an original and substantial contribution, and careful disclosure of relevant interests. Human research also emphasizes an awareness that findings can lead to new treatments and changes to existing guidelines.

Communication about research findings (including non-scientific expressions and public appearances) is fair and careful, and does not raise expectations that cannot be met. Above all, the ethical handling of research data applies, as described in the KNAW recommendation "Responsible research data management and the prevention of scientific misconduct" (2012).

Independent and impartial
During the investigation process, justice is displayed to all interests and interested parties. The knowledge transfer of research results is unbiased, and is based on the current state of science. Objectivity of substantive knowledge is not damaged by personal preferences or (financial) interests. When considering different interests, the scientist may sometimes encounter moral dilemmas, with different values coming into conflict with each other. If doubts about impartiality and objectivity arise, the researcher consults experts and seeks dialogue, maintaining openness about facts, motives and their own interests.

Responsible and reliable
The scientist can fully account for their scientific work with valid arguments. This way, they can justify their own work while contributing to an honest and fruitful research climate. Taking and giving scientific responsibility requires a high level of knowledge and skills, along with insight into the limits of one’s own expertise.

Anyone suspecting or observing a violation of scientific integrity – within or outside of their own research group – is obliged to take action. If possible, the person involved in undesirable behaviour is directly addressed. If this has insufficient results, or is not possible or desirable, the behaviour is raised via hierarchical lines. The scientist can speak to an Erasmus MC Confidential counselor at any time.

Respectful
The researcher must treat patients/test subjects and test animals with respect. A respectful attitude of basic appreciation is also self-evident towards colleagues, subordinates and managers. The doctor or scientist remains aware at all times of the interests of the patient/test subject or test animal. The senior scientist takes responsibility for the junior researcher, student researcher or doctoral student through good mentorship, and does not abuse the
hierarchical dependency relationship. The junior researcher is aware of their responsibility and does not behave in a way that exceeds their powers and abilities.

1.6 Managing within an ethical research and education environment

As a (bio) medical scientific research organization, the Erasmus MC is more than the sum of its individual researchers. Mutual trust is the basis on which joint research projects are established. Managers, in particular, determine a climate in which ethical scientific practice can flourish. They are expected to maintain the preconditions set out in the Research Code and to fulfill an exemplary role in this regard.

Managers are aware of potential pitfalls when concluding agreements for conducting (bio) medical scientific research, and when valorizing (the economic and/or social ‘marketing’ of) research results. After all, there is always the chance of a conflict of interest or the appearance thereof. Good agreements, transparency and ongoing dialogue about inevitable dilemmas that will arise in this context are therefore essential.

Special attention and care are required when it comes to the education and training of researchers. Within the Bachelor’s and Master’s programs, attention is paid to the responsible practice of scientific research. In the courses offered to PhD students, academic integrity is part of the curriculum at both the university and faculty levels. This obligation also applies to researchers-in-training as they follow courses in areas such as the design and implementation of human-related research, animal testing and basic statistics.

Managers are aware of their example-setting role, as well as the importance of their role as mentors, influencers, and discussion partners for prospective researchers and research staff, especially in the areas of scientific integrity. The Erasmus MC encourages and facilitates them to shape research in accordance with applicable laws and regulations.
2. LEGISLATION AND REGULATIONS, THE ERASMUS MC POLICIES AND GUIDELINES

2.1 General

This chapter provides a description of (inter)national laws and regulations in the field of scientific integrity in relation to (bio) medical scientific research. Every researcher in the Netherlands is expected to act in accordance with these regulations. Erasmus MC applies all these laws and regulations or has its own policies and / or guidelines based on these laws. The additional policy rules and guidelines specific to the Erasmus MC are provided in separate boxes, and sometimes supplemented with practical information. The following areas of application are distinguished:

- Research with patients and other test subjects
- Research with body materials and patient data
- Research with laboratory animals
- Data management
- Publishing
- Relationships with third parties
- Intellectual property

The Erasmus MC general rules and guidelines

Scientific integrity is part of integrity in a broader sense. In other words, acting with integrity is not just limited to specific activities. It is a matter of mentality and awareness, and is therefore always present. Integrity affects the Erasmus MC's 'corporate identity'. The integrity of an organization stands or falls with the integrity of its individual employees. The Erasmus MC has rules and guidelines in all areas to promote ethical behaviour among all employees. You can find the following topics on the intranet:

- The Integrity is part of the Erasmus MC brochure (Dutch)
- An explanation of ancillary activities, inducements and financial conflicts of interest (Dutch)
- The Conflict Resolution Directive (Dutch)
- Media protocols (Dutch)
- The Information security policy (Dutch)
- The Whistleblower procedure (Dutch)

Suspected scientific misconduct

All people within the Erasmus MC take their own responsibility for maintaining scientific integrity. To this end, the general principles of professional scientific conduct must be observed at all times. The Dutch Code of Conduct for Scientific Research Integrity elaborates on these principles, which are also endorsed by the Erasmus MC.

One of the ways we test academic integrity is to provide the right to submit a
report if anybody suspects that a former or current employee and / or student of the Erasmus MC has violated scientific integrity. Of course, the Board of Directors can also decide to initiate or arrange for investigation in the event of a possible violation of scientific integrity. This regulation is based on the National Scientific Integrity Complaints Procedure Model (VSNU, 2019, Dutch) from the Association of Universities in the Netherlands. A description of the implementation of this reporting right can be found in the Erasmus MC Scientific Integrity Complaints Procedure.

2.2 Research with patients or other test subjects

In research, the role of the scientist can be twofold: as a researcher and a practitioner. This dual role entails specific tasks and responsibilities. The researcher knows that tension can arise between their research and the interests of patients and other test subjects. For contract research, tension can also arise between these interests and the financier of the research. The researcher always guarantees the interests of patients and other test subjects. This protection of the interests of test subjects is laid down in legislation and regulations. The sources on which the regulations are based are discussed below.

Declaration of Helsinki (1964, last update in Fortaleza, Brazil, 2013)

This statement is the basic document for the protection of test subjects in medical scientific research. The statement is available on the website of the World Medical Association (WMA).

Guideline for Good Clinical Practice-ICH (2001/20/EG, last update in November 2016)

In the Netherlands, drug research must comply with the International Conference Harmonization (ICH) Good Clinical Practice (GCP) guidelines. In addition, study medication must comply with Good Manufacturing Practice (GMP) guidelines. Laboratory research takes place in laboratories that work with a quality system, such as Good Laboratory Practice (GLP), ISO standard 17025 (for test laboratories), or 15189 (for medical laboratories). The ICH-GCP directive can be downloaded on the website of the ICH.

Medical Devices Regulation (MDR, 2017/745 and 2017/746, comes into effect in 2020 and 2022)

Medical devices and medical devices for in vitro diagnostics make an important contribution to the quality of life and the health of patients. They include a varied group of products – from bandages, artificial hips and pacemakers to laboratory and self-testing equipment.


International Ethical Guidelines for Health-related Research Involving Humans (Council for International Organizations of Medical Sciences, 2002, last update 2016)

The CIOMS, which operates under the auspices of the WHO, has the task of operationalizing ethical principles of good scientific research with test subjects for research practice. The guidelines issued by the CIOMS try to make clear how ethical principles can be applied effectively in practice.
Medical Research Involving Human Subjects Act (WMO 1998, last update in August 2018)
The Medical Research Involving Human Subjects Act (WMO) relates to scientific research in which people are subjected to actions or rules of conduct imposed upon them. The requirements that the WMO sets for research can be found on the site of the Central Committee on Research Involving Human Subjects (CCMO): Legal framework for medical scientific research. The WMO’s purpose is to offer test subjects good legal protection and to legitimize bona fide research. For research with minors and incapacitated test subjects, we refer to the following CCMO memorandum: Therapeutic vs non-therapeutic research on minors and incapacitated test subjects (January 2017, Dutch). For information about the assessment of resistance during participation, see: Codes of conduct with regard to the resistance of persons unable to act.

Ethical Review of research with patients / subjects
Every research project with patients / test subjects must be submitted to an accredited Medical Research Ethics Committee (MREC) in advance. The MREC first performs an initial assessment as to whether the project falls within the scope of the WMO. If the project does fall within the scope (and is therefore subject to) the WMO, the research protocol is assessed by the MREC against the WMO. Only approved projects may be implemented in accordance with the approved protocol.

The Erasmus MC MREC
The Erasmus MC MREC (Medical Research Ethics Committee) is a committee recognized by the CCMO on the basis of Article 16 from the WMO. It acts as an independent administrative body, and derives its tasks from the WMO. Please note that the MREC does not perform ‘retroactive reviews’. This means that research protocols must be submitted to the MREC in advance so that it can implement its WMO review. The MREC procedures are described on the Erasmus MC website.

Quality assurance for human research 2019 (NFU, March 2019)
The Guideline on Quality Assurance for Human-Related Research (Dutch) is aimed at quality assurance for research that is subject to the WMO, but it can also be used for other medical-scientific research with test subjects. The safety of test subjects and the quality of the scientific results are central. The aim is to minimize any participation risks and disadvantages for test subjects. Such risks must always outweigh the added value that can be expected from conducting the research. Topics covered include risk classification, monitoring, reporting to the client and archiving, as well as training and auditing.

Erasmus MC as the provider of research subject to WMO
In 2012, the Erasmus MC formulated policy measures for clinical research. The policy concerns research that is subject to WMO, that is investigator-initiated, and for which the Erasmus MC is the sponsor. These policy measures (Dutch) include a mandatory monitoring plan, the decision to deploy a Data Safety Monitoring Board, and the mandatory use of an automated Clinical Data Management System.
**BROK**
The e-learning module Introductory Course in Regulation and Organization for Clinical Researchers (eBROK) was developed by the Netherlands Federation of University Medical Centres (NFU). It teaches researchers the laws and regulations that apply to people-related research. Information about how to take the BROK course is described in the BROK course’s Training and Exam Regulations.

**BROK at the Erasmus MC**
Clinical researchers conducting research covered by the WMO within the Erasmus MC are required by the Board of Directors and the MREC to obtain a BROK® certificate before or within 6 months of starting the study. Clinical researchers are understood to mean scientific researchers with the daily responsibility for conducting the research with patients and other participants. The principal investigators are also required to obtain a BROK® certificate. The BROK® obligation does not apply to researchers who exclusively conduct non-WMO research.

**Trial register**
The Vancouver Group, a joint venture of major medical science journals, decided in 2004 to only accept clinical trials for publication if they are officially registered with a recognized trial register. The purpose of this condition is to identify potential publication bias and reduce any related adverse effects. Researchers must register their clinical trials in advance with a recognized Trial Register, such as the Dutch Trial Register (www.trialregister.nl) from The Dutch Cochrane Center – a collaboration including, the Ministry of Health, Welfare and Sport, Nefarma (now the Association Innovative Medicines) and the CCMO. Other recognized trial registers are the ISRCTN registry (UK), ClinicalTrials.gov (USA), the EU Clinical Trials Register and the WHO International Clinical Trials Registry Platform (IC TRP).

**The registration of clinical trials conducted by the Erasmus MC**
All principal investigators employed by the Erasmus MC must register their clinical trials in the Dutch Trial Register. Researchers must register prospective comparative human-related medical examinations prior to the start of the study. The registration of experimental intervention research is mandatory. It is not mandatory for observational research. Research that is subject to the WMO must always be registered in the Dutch Trial Register.

**Codes of conduct with regard to resistance from the incapacitated**
Researchers conducting scientific research with the participation of incapacitated test subjects must adhere to the following codes of conduct. It is essential to interpret signals that the test subject no longer wants to participate in the study.

The concept of 'resistance' in the context of the Medical Research involving Human Subjects Act (WMO) is further elaborated in three codes of conduct: resistance from incapacitated geriatric and psychogeriatric patients, resistance from minors participating in medical research and resistance from people with mental disabilities.

**General Data Protection Regulation (GDPR, May 2018)**
The General Data Protection Regulation (GDPR) is the privacy legislation for the entire
European Union. The GDPR strengthens and expands privacy rights, gives organizations more responsibilities when it comes to the collection and processing of personal data, and gives the same powers to all European privacy regulators. This also has consequences for the collection, storage and processing of personal data in medical research.

Support services within the Erasmus MC

Consultation Centre for Patient-related Research (CPO)
The mission of the CPO is to stimulate and maintain the Erasmus MC’s top position in clinical research. The consultants advise Erasmus MC researchers, from junior to senior, in many aspects of research. Researchers can contact the consultants directly or first make an appointment to discuss the specific question with the CPO coordinator.

Clinical Trial Agreement
The Erasmus MC’s Technology Transfer Office (TTO) answers questions about drawing up and concluding a Clinical Trial Agreement. This also applies to the use of a model agreement between the NFU and members of the Association Innovative Medicines.

Privacy Knowledge Office (PKO)
The Privacy Knowledge Office (PKO) is the knowledge center and source of information for everything in the field of GDPR. Questions can be directed to pko@erasmusmc.nl.

2.3 Research with human tissue and patient data

Biobank materials are collected prospectively (de novo), so that they can be used later for new research questions. Possibilities for scientific research with human tissue and associated medical, genetic and other data from patients are increasing, partly due to the emergence of prospective biobanks such as the Parel snsnoer Institute (PSI). PSI is run under the administrative responsibility of the Netherlands Federation of University Medical Centres. PSI has partnerships with other (inter) national biobank initiatives such as BBMRI, Lifelines and TraIT. It will eventually be transformed into a facilitating infrastructure within Health-RI (Health Research Infrastructure Initiative). This type of prospective research does not fall within the scope of the WMO (it is non-WMO research). However, this does not alter the fact that non-WMO research is also subject to clear rules and must be tested in advance. Legislation is currently being prepared in this area – in particular for body tissue. Researchers who use body tissue or patient data must take into account the following laws and rules of conduct:

Code of conduct for health research with body tissue (Code of Conduct for responsible use, Federation of Medical Scientific Associations, 2011, with postscript in 2015)
These rules of conduct are intended for scientific researchers who want to use anonymous or coded human tissue. They also apply to the further use of biobank body tissue that was initially purchased for a different purpose, such as diagnostics. In addition, they apply to prospective (de novo) biobanks, where biomaterials are collected for future scientific research that is not further defined. The design and implementation of these biobanks must follow the guidelines of the Code of Proper Use.
**Declaration of Taipei (2002, latest changes in Taipei, Taiwan, 2016)**

The “Declaration of Taipei on ethical considerations regarding health databases and biobanks” is a supplement to the Declaration of Helsinki regarding the rights of individuals who provide their tissue or data for research and other purposes based on confidentiality and privacy rules. The English-language statement is available on the World Medical Association (WMA) website.

**Control at the Erasmus MC**

The following principles apply to the ownership of biomaterial for prospective biobanks at the Erasmus MC:

Partial control over biomaterials and associated data is obtained on the basis of permission given by the Donor. A person who has handed over body tissue to the Erasmus MC has control over the material and can partially transfer it to the Erasmus MC via Informed Consent. The specific type of transfer control is determined by written patient/subject information and Informed Consent. The Erasmus MC delegates provide control to the scientists employed by the Erasmus MC, who thereby acquire the right to use this material for a specific purpose and for a specific period.

The Donor may withdraw Consent at any time, in part or in its entirety, free of charge and without stating reasons. Instructions for this are described in the information given to the patient when they sign Informed Consent. After permission withdrawal, no new body tissue or data will be collected from the Donor for medical scientific research. Biomaterials that have only been collected for scientific purposes and have not yet been released from the biobank for that research will be destroyed. Any residual material still available, primarily collected for diagnostics, will be marked in such a way that the biomaterials will no longer be issued for scientific research, but will remain available for diagnostics.

Data and images that have been made available for specific research by the biobank prior to consent withdrawal will remain available in the same form for the purposes of that research and within applicable laws and regulations. The written information through which the Donor has granted earlier permission must include a section stating that, when withdrawing permission, bodily material that is already under investigation cannot be destroyed.

For further use of biobanks, a specific no objection system applies as described in the Code of Proper Use.

**Available infrastructure for the collection of biomaterials and associated data**

**The Erasmus MC-wide Biobank**

The Erasmus MC Central Biobank (ECB) is one, centrally-directed, Erasmus MC-wide biobank consisting of different structured collections of human-derived materials (including cell lines, organoids and xenografts) and/or images linked to related clinical and/or epidemiological data, available for scientific research.
In order to guarantee the quality of the samples and to promote the reproducibility of results, biomaterials can be collected via the Erasmus MC Central Biobank collection points, such as Clinical Chemistry and Pathology. Work can also be done before and after saving the samples. Centralized and standardized storage can also be arranged via this service platform.

A new central biobank regulation was adopted in October, 2018. The regulation applies to the collection, storage, publishing and use of all human tissue and associated data for medical scientific research at the Erasmus MC. These collections are managed and documented by the ECB.

This regulation does not include:
- The use of human embryonic or fetal tissue for scientific research, regardless of how it was obtained. Requests must be submitted to the CCMO in accordance with the Embryo Act.
- Collections of body tissue primarily intended for therapeutic purposes or any other reuse in or on the patient.
- The storage of tissue that originates from a human body and has been made available to science.

**The Parelsnoer Initiative (PSI) at the Erasmus MC**
The Erasmus MC participates in several projects (called ‘pearls’) under the Parelsnoer Initiative. It is currently the national coordinator for Ischemic Heart Diseases (IHD) and Neurodegenerative Diseases (NDD). Every UMC is responsible for the local infrastructure and coordination of local biobank activities. The PSI UMC coordinator of the Erasmus MC and the PSI Erasmus MC ICT coordinator take on local supervision of the scientists to enable participation in each ‘pearl’ (disease).

**Laws regulating germ cells and embryos (Embryo Act 2002, last change September 2013)**
The Embryo Act (Dutch) stipulates that research with (residual) embryos must be assessed in advance by the Central Committee on Research Involving Human Subjects (CCMO). Research on reproductive cells made available specifically for this purpose must also be assessed in advance by the CCMO. The Ministry of Health, Welfare and Sport has drawn up a manual for the practical application of the Embryo Act.

**Code of conduct for the use of personal data in scientific research (2005, consultation version 2017)**
The Association of Universities in the Netherlands (VSNU) has drawn up a Code of Conduct (Dutch) for the use of personal data in scientific research. The Code of Conduct states that data that could be traced back to persons must be destroyed after research, unless there are compelling arguments that make it necessary to keep the data for longer.

**Code of conduct for health research with patient information (Code of Conduct for the Use of Data in Health Research, Federation of Medical Scientific Associations, 2003, status 2014)**
The Code of conduct for health research is intended for care providers and / or scientific
researchers who want to make use of anonymous or coded patient data. The code of conduct contains rules for protecting the rights of participants in data research. For the purposes of this Code of Conduct, research is defined as: medical research (such as patient-related research, epidemiological or health care research) using data that is already available or can be collected for that purpose, and to which professional secrecy applies as defined in Article 88 of the Individual Healthcare Professions Act.

Health research within the meaning of this Code of Conduct does not include scientific research as referred to in the Medical/Scientific Research involving Human Subjects Act (WMO) and as described in Article 1b of that Act.

**Research with patient data at the Erasmus MC**
For information about the use of personal data in scientific research, please contact the Privacy Knowledge Office at pko@erasmusmc.nl.

### 2.4 Research with laboratory animals

The law states that the use of animals for research and education is not permitted unless justified by the importance of the goal, and unless the results cannot be obtained otherwise. A recognition of the intrinsic value of the animal comes first.

**The Experiments on Animals Act (last revision in December 2014)**
The Experiments on Animals Act, the Experiments on Animals Decree and the Animal Testing Regulation (all Dutch) help to implement Directive 2010/63 / EU. They focus on the responsible use of laboratory animals and limiting animal testing as much as possible according to the 3R principle: Replacement, Reduction and Refinement. New elements also include transparency (inter alia the publication of non-technical summaries of granted project permits) and the specific competences of employees who work with animals (care, handling, and killing) or who determine the design of the research.

**Ethical assessment of research with laboratory animals**
Animal testing may only be conducted in the context of a project for which a project permit has been granted. Project permits are issued for a maximum of 5 years by the national Central Animal Testing Committee (CCD, Dutch), an independent administrative body. The project permits must be applied for by the institution's permit holder. The permits are issued to the institution's license holder. The responsible researcher is primarily responsible for implementation in accordance with the permit.

Each license holder must establish an Animal Welfare Authority (IvD) for:
- advice on animal welfare and best practices, including outside the implementation of projects;
- supervising the implementation of projects and checking compliance with the permit;
- assessing and advising on test designs and proposed methods;
- advising on 3R alternatives and evaluating animal tests with a view to this.

The development and implementation of alternatives must always have the attention of every researcher who works with laboratory animals.

The license holder must designate named persons for:
- monitoring compliance with the law;
- promoting and monitoring the competence (expertise and ability) of employees for their work, including the availability of information in that context;
- responsibility for the care and welfare of the animals;
- expert veterinary supervision of animal welfare.

These functions are embedded in the IvD, including the implementation of the institution’s various registration and reporting obligations.

The IvD advises on the preparation of project proposals before they are submitted to the CCD for testing. New project applications are only offered by article 9 group leaders / principal investigators (PIs) and are supervised by the IvD in order to ensure high-quality application.

The CCD determines whether a project permit is granted, partly on the basis of the advice of the Animal Experiments Committee (DEC). Institutional license holders may express their preference for a specific DEC when submitting a project license application to the CCD. The CCD generally follows that preference, but can also submit the request for advice to another DEC.

Based on the project permit application, a DEC tests whether the importance of the animal test outweighs the degree of discomfort the test animal will experience. It must also be clear that no real alternatives are available. If the use of laboratory animals is unavoidable, their welfare must be guaranteed as far as possible, and the number of laboratory animals must be limited to what is necessary to achieve the objective.

**The Erasmus Experimental Animal Center**
The Erasmus Experimental Animal Center (EDC) is the centralized facility for animal experimental research at the Erasmus MC. The EDC supports the organization and the researchers in complying with the specific laws and regulations concerning the keeping and use of (test) animals. It provides the acquisition, accommodation and care of laboratory animals and support in the conduct of animal testing in a broad sense, including the care of animal health and welfare, and the environment. It offers facilities and support for conducting animal experiments, the targeted education and training of practitioners, professional assistance, and the use of equipment. The Responsible use of animals, human and animal safety and the quality of research are paramount.

**Animal Experiments Committee**
The Erasmus MC employs a recognized Animal Experimental Committee (DEC) when applying for permits.

**The Article 9 officer within the Erasmus MC**
A researcher who wishes to conduct animal experiments must meet the requirements for expertise set out in Article 9 of the Animal Testing Act. The researcher must be an expert in the field (holding at least a relevant Masters degree) and must have successfully completed a course in laboratory animal science. The course focuses on the careful and responsible use of laboratory
animals in research, and results in the official designation as an Article 9 officer. Masters degrees within the European economic area are accepted without additional assessment. Additional assessment is necessary for recognition in all other situations.

Animal-specific knowledge is also required to set up animal tests, and to carry out actions on animals. The specific competence (expertise and ability) must be additionally demonstrated or acquired. Employees who care for, treat or kill animals must be qualified to do so, as holders of a legally-recognized diploma, supplemented by demonstrable practical competence (expertise and ability). There is no automatic international mutual recognition of qualifications. Foreign qualifications have to be assessed, and exemption is possible in some cases for the performance of specifically-mentioned activities.

2.5 Research with GMOs and infectious agents

Research with GMOs has various applications. This doesn’t just concern in vitro research, but also research with laboratory animals (in vivo). GMOs are also increasingly being used in patients (gene therapy). The legislation and regulations for work with GMOs consist of the Decree on Genetically Modified Organisms in the Environment 2013 (Decree on GMO / Regulations on GMO). Information about working with GMOs, legislation and regulations and the permit database can also be found on the website of the National Office for GMOs. In addition, information can be found on the website of the National information Point for Access and Distribution of Benefits.

Nagoya Protocol (EU Regulation 511, 2014)

The Nagoya Protocol describes the rights and obligations for countries that have signed it. As of October 2014, the protocol gives countries that possess genetic resources the opportunity to request compensation from citizens and companies that obtain and use these resources. This compensation must be reasonable and equitable, and countries may not refuse access to these resources. The countries in which users are located have an obligation to monitor users for the correct use of these resources.

Nagoya Protocol Implementation Act (2016, last change January 2019)

The Netherlands adopted the Nagoya Protocol Implementation Act (Dutch) on 16 April 2016. As a result, there is now supervision of the careful use of genetic material in the Netherlands. The NVWA (Netherlands Food and Consumer Product Safety Authority) carries out this supervision. More information can be found on the website of the National Contact Point.

Scientific research with GMOs at the Erasmus MC

The Erasmus MC has appointed Biosafety Officers (BVF, Dutch). The Board of Directors has mandated duties to these BVFs. This means that they provide information and advice on behalf of the Board of Directors, and monitor and supervise work with GMOs that takes place under restricted use. The Biosafety Officers report directly to the Board of Directors; the latter is ultimately responsible.

Similar restriction requirements based on the Working Conditions Act apply to
working with classified infectious agents. The BVFs are also responsible for supervising the application of restriction measures in the context of research.

The Erasmus MC also has Environmental Safety Officers (MVFs) who are responsible for work with GMOs that does not take place under adequate physical restriction, such as clinical gene therapy. The Environmental Safety Officers are comparable to Biosafety Officers. On behalf of the Board of Directors, they coordinate work with GMOs that are introduced into the environment, and supervise the implementation of this work.

Compliance with the Nagoya Protocol within the Erasmus MC

Researchers at the Erasmus MC are responsible for the careful use of genetic resources that fall under the Nagoya Protocol. Documentation demonstrating compliance with this legislation should be kept for 20 years. This documentation should consist of at least prior informed consent (PIC) and mutually agreed terms (MAT). Further information is available through the BVF and / or TTO.


As one of the first countries in the world, the Netherlands has a code of conduct for Biosecurity (Dutch). This code of conduct for researchers is aimed at raising awareness of the potential risks of misuse of life science knowledge. The code was drawn up by the Biosecurity Working Group, which was set up for this purpose by the Royal Netherlands Academy of Arts and Sciences (KNAW) and is intended for knowledge and research institutions. The code of conduct provides rules for responsibilities and provides starting points for management and sanctions.

2.6 Data management

As an employer, the Erasmus MC is designated by Dutch Copyright Law as the economic owner of all works and new inventions by a researcher. This includes research data (see the Intellectual Property section below). Researchers are expected to collect, process and store research data in accordance with applicable guidelines. The Netherlands Code of Conduct for Research Integrity emphasizes the importance of the verifiability of research results.

For more information about handling research data, we refer to the KNAW publication Responsible research data management and the prevention of scientific misconduct. In addition, the NFU has started a Data4lifesciences initiative. The first result of this initiative is a ‘living’ document called HANDS (Handbook for Adequate Natural Data Stewardship), a digital handbook for good data stewardship. The associated FAIR data principle (Findable, Accessible, Interoperable, Reusable) is widely recognized in the Netherlands.

Retention and storage periods

There is still no clear legal framework for the retention and storage periods for data (and human tissue) for scientific research. If the research is subject WMO, the Erasmus MC position is to retain all documentation and data for 15 years after the research has been completed / published. However, data from studies with cell or tissue products are retained for 30 years.
For all non-WMO research (including basic and pre-clinical research), a retention period of at least 10 years applies unless there are other agreements to keep it for a shorter or longer period.

**Personal research data**
Agreements for handling personal research data within the Erasmus MC are laid down in the Erasmus Data Protection Regulations for Patients (2016). Further information can be found on the Legal Affairs website.

**Sustainable data storage**
International guidelines are available for sustainable long-term archiving. The simplest set of criteria is that of the international CoreTrustSeal. These criteria and the associated quality seal are independent of the given field of expertise. An archive that stores data in a sustainable way has a ‘trusted digital repository’ certificate. In the Netherlands, CentERdata, DANS and 4TU.ResearchData have this certificate. SURF will soon have this too.

**Research data management at the Erasmus MC**
Research grant organizations are increasingly making structural data management compulsory. Horizon2020, ZonMw, NWO and other organizations have good reasons for this. After all, good data management promotes scientific integrity and increases the impact of research. At the same time, ‘open data’ and the sustainable availability of research data funded by public funds for reuse are also increasingly mandatory.

The main requirements are as follows:
- A research request must be provided with a data management section describing how people will handle the data.
- After the application has been approved, the researcher must develop the data section into a data management plan within 4-6 months. This section must describe in more detail how they will deal with data.

**Data systems in the Erasmus MC**
The Erasmus MC offers researchers a variety of data management and storage solutions:
- Gemstracker is the data management system for observational follow-up studies
- Open Clinica is a data management system for clinical trials
- LimeSurvey is a system for the development of digital questionnaires
- Digital storage: archive and online storage services

### 2.7 Publications

**General**
A scientific publication formally informs other researchers about the results of research, and offers third parties the opportunity to test the quality of that research. The starting point is that all research results should be available for publication in scientific or professional literature, independently of funding and regardless of the outcome. Publishing is of great importance for science, the career of the individual employee and the institution.
Clinical and biomedical research is increasingly becoming multidisciplinary or multicentre. As a result, publications almost always have several authors. In addition to the fact that a researcher is an author, the order of authorship also plays a role. This position says something about the nature and weight of the contribution they have made to the research. Although scientific journals sometimes provide guidelines for describing author contributions, in most cases there is no conclusive regulation that defines which contribution justifies which author’s position.

General principles for publication are laid down in national legislation (in particular in the Dutch Copyright Law, last update October 2018). High-quality scientific publications and peer reviews meet certain due diligence requirements laid down in guidelines drawn up by international committees, as shown in the overview below.

**International Committees and the ethics of scientific publishing (last update December 2018)**
The International Committee of Medical Journal Editors (ICMJE), formerly the Vancouver Group, provides information and consensus guidelines on ethical issues related to publishing in biomedical journals, such as authorship requirements, potential ‘conflicts of interest’, and duplicate publications.

The Committee on Publication Ethics (COPE) is concerned with the integrity of the peer review process for scientific publications, in particular within the biomedical sciences. The Guidelines on Good Publication Practice can be found under Code of Conduct at http://www.publicationethics.org/.

**EQUATOR network: Enhancing the QUAlity and Transparency Of health Research**
EQUATOR is an international initiative with guidelines for reporting on various types of research. This includes:

<table>
<thead>
<tr>
<th>Guidelines for reporting on the main forms of research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised trials</td>
</tr>
<tr>
<td>Observational studies</td>
</tr>
<tr>
<td>Systematic reviews</td>
</tr>
<tr>
<td>Study protocols</td>
</tr>
<tr>
<td>Diagnostic/prognostic studies</td>
</tr>
<tr>
<td>Case reports</td>
</tr>
<tr>
<td>Clinical practice guidelines</td>
</tr>
<tr>
<td>Qualitative research</td>
</tr>
<tr>
<td>Animal pre-clinical studies</td>
</tr>
<tr>
<td>Quality improvement studies</td>
</tr>
<tr>
<td>Economic evaluations</td>
</tr>
</tbody>
</table>

**CCMO statement on publication policy, March 2002**
When assessing a protocol, medical ethics review committees must take into account the
agreements made by those who conduct and perform WMO research. In this statement, the CCMO has laid down its principles regarding the disclosure of research data. This concerns, for example, the rights of different parties involved in an investigation, and the requirement that unforeseen or negative investigation results also be published.

**Open Access, Plan S**
Open Access is a broad international academic movement that strives to make scientific information free and accessible online. The principles of Open Access were laid down in 2003 in the Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities. This statement has been signed by all Dutch universities and research organizations.

**Quality and Predatory Journals**
Open Access journals are not by definition of lesser quality than traditional journals. However, there are publishers who abuse the open access model to make money. They charge fees for making publications accessible without organizing editorial services and peer reviews. Information about journals can be found on the websites below:

- DOAJ (Directory of Open Access Journals). All the journals included here have been screened for quality procedures.
- List of Predatory Publishers. This list contains the names of publishers and journals that may abuse the open access model.

**CRediT**
Since 2014, the contributor taxonomy – otherwise known as CRediT (Contributor Roles Taxonomy) has been widely adopted across a range of publishers. CRediT is a new approach to authorship which aims to capture the various contributions that go into scholarly work by providing 14 defined roles. The roles are intended to provide greater recognition for the work of each author, reduce authorship disputes, and facilitate collaboration. Not all roles may apply to every paper and each author is likely to have contributed in multiple roles.

**Publishing guidelines at the Erasmus MC**
The starting point for the Erasmus MC is that all results from research carried out at the Erasmus MC must be published. Furthermore, it is not acceptable for industry or other financiers or sponsors to influence the content of scientific publications.

On the other hand, the Erasmus MC is prepared to make agreements about a reasonable period for publication postponement (up to a maximum of 60 days), so that patent applications can be filed in time and the research partner can become acquainted with the content and possibly comment on it. Information that comes entirely from a research partner (and is therefore not generated by the Erasmus MC) remains the property of the research partner and cannot be published.

The department head has the responsibility within their department to create an environment in which authorship and order of authorship fits as much as possible within the principles of this guideline.
Preconditions for authorship at the Erasmus MC

The starting point for publishing is the ICMJE consensus guidelines, supplemented with the following preconditions:

- Each author must make a substantial contribution to the creative idea, design or execution of the research described in the article and / or to the analysis or interpretation of the data.
- Each employee who makes a substantial (intellectual) contribution to the research, such as drafting or critically commenting on at least a part of the intellectual concepts, is an author of the article.
- Each author has approved the latest version of the entire manuscript, in particular their own contribution. Journals usually demand that all authors sign a statement confirming authorship, sometimes describing the nature and extent of each author’s contributions.
- One of the authors takes responsibility for the total article (in principle, this is also the author to whom correspondence is addressed).
- The routine provision of data or material or the provision of financial resources does not justify co-authorship. Mentioning ‘acknowledgments’ or an overview of contributing persons can do justice to the intended contribution.
- ‘Gift authorships’ are undesirable.
- Authors are obliged to state potential conflicts of interest, ranging from sponsorship by third parties to the financial interests of each of the authors (disclosure).
- Clinical research must be registered prior to publication in (inter) national databases in conformity to the requirements of clinical journals.
- A non-exhaustive list of possible contributions from authors:
  • Initiating the research
  • Designing the research
  • Designing questionnaires
  • Contributing to new reagents or analysis methods
  • Conducting research
  • Collecting data in combination with another contribution
  • Administrative, technical and material support in combination with another contribution
  • Data analysis
  • Writing important parts of the article
  • Writing and approving the final manuscript
  • Providing commentary on drafts
  • Contributing academic expertise from an Erasmus MC Core Facility

Author position

- Author order must be established through a joint decision by all authors. Agreements about authorships are preferably made in advance.
- The first author is the researcher who has contributed the most to the project, including implementation (for example, a PhD student or a post-doc).
The last author has often generated the creative idea for the research and has supported it. The last author is generally the group leader. 

**Author affiliation**

- An author indicates affiliation to the Erasmus MC if the research is largely carried out under the responsibility of the Erasmus MC, using the research infrastructure and expertise available there.

- A new researcher appointed at the Erasmus MC can still indicate their old institution as an affiliation for publications for research that has been carried out (for the most part) at the old institution. The researcher can, of course, indicate that the corresponding address has changed. Conversely, an Erasmus MC researcher who is going to work elsewhere can also indicate the Erasmus MC in publications about research that was carried out (for the most part) during their appointment at the Erasmus MC. In view of the above principles, it is ultimately up to the researcher, in consultation with the department head, to make an assessment of the extent of the contribution to an article from the various institutions to which they have been appointed.

- The Erasmus MC maintains, just like other University Medical Centres in the Netherlands, that only publications that actually state affiliation to their own institution are counted as their own production.

**Open Access within the Erasmus MC**

All authors from the Erasmus MC and Erasmus University Rotterdam (EUR) are obliged to offer their publications in Open Access via the repository of the EUR: RePub. The latest author's version can be placed in RePub immediately, or after an embargo period, if the journal publisher's policy allows this.

**Prevention of publication bias**

The Erasmus MC attaches importance to the publication of all data, including data that does not confirm a research hypothesis. This can be published, for example, in specialized journals, so that these publications can be cited, making the data available to a broad (scientific) audience.

**Reference checks for dissertations**

Since September 2015, PhD regulations have included a stipulation that a supervisor must perform analysis through a plagiarism scan (reference check) during the assessment period within which the doctoral thesis is definitively approved. At the Erasmus MC, this reference check is carried out by the Medical Library.

**Assessment of scientific publications and research proposals**

The assessment of scientific publications and research proposals from 'peers' is an important part of a researcher’s work. These assessments by reviewers for articles and research proposals have serious consequences for the researchers involved. It is therefore important that the assessment is always characterized by high quality, respect and impartiality. The reviewer must also guarantee the ownership of ideas and confidentiality at all times. It is of great importance that a reviewer does not
respond to a request to review a scientific article or research proposal if the reviewer cannot comply with the above. The starting points here are:
- The reviewer has no interest in a positive or negative assessment.
- There is no (apparent) conflict of interest: no involvement with the document to be assessed and no involvement with the applicant or co-applicants.
- The content of the document does not exceed the expertise of the reviewer.

**Points of attention for the assessment**
- A reviewer starts the assessment with a description, in their own words, of the structure and content of the document being assessed.
- A reviewer always provides constructive feedback.
- A reviewer provides a good foundation for points of criticism, with references and suggestions for improvement where possible.
- A reviewer distinguishes between personal preference and scientific inaccuracies.

If fraud is suspected, it is in the interest of science to inform the editor of the journal in question, or the scientific advisory board of the relevant subsidy provider, along with stated arguments and reasons.

### 2.8 Codes of conduct in relationships with third parties

**Guidelines of the Foundation for the Code for Pharmaceutical Advertising (CGR) and the Code of Conduct Advertising for Medicinal Products (2014, latest changes July 2019)**
The CGR, established in 1998, is responsible for the design and implementation of self-regulation in the field of pharmaceutical advertising aimed at professionals. The CGR has set up an assessment framework to formulate a code of conduct that is elaborated in guidelines and guiding principles. Some of these also relate to clinical scientific research. Chapter 6 of this code of conduct states, among other things, the permitted conditions for the sponsorship of scientific research. Chapter 7 discusses openness about financial relationships. For more information, see the CGR website [Code of Conduct Pharmaceutical Advertising for Medicinal Products](https://www.cgr.nl) and the [Policy Rules for the Medicines Act](https://www.cgr.nl).

**Code of Conduct Medical Devices (2014, last update January 2018)**
The Code of Conduct Medical Devices aims to give further substance to careful, transparent and responsible interaction between suppliers of medical devices and the parties involved in decision-making regarding the purchase and/or application thereof, regardless of the setting in which they operate.

**NFU Company Inducement Guideline (2010)**
The Dutch University Medical Centers apply the frameworks set out in the Medicines Act when dealing with pharmaceutical companies. The NFU has further elaborated on the “further interpretation of the concept of inducement” policy rules:

**Definition of “inducement” according to the Medicines Act**
Inducement means the provision, offering or granting of money, services or goods that can be valued for money for the apparent purpose of promoting, prescribing or using a medicine. In this context, inducement is considered equivalent to making an offer to promote the
prescription, distribution or use of a medicine with the apparent purpose of receiving money, services or goods that can be valued for money, or accepting such funds, services or goods after having made an offer to promote the prescription, distribution or use of a medicine.

The starting point for inducement rules according to the Medicines Act
In practice, there are a variety of relationships between companies and professionals. However, this does not mean that all of these relationships can, by definition, be regarded as an inducement. The starting point is that the patient / consumer must be able to count on objective information about – and a sound choice for – a medicine. Quality of care and the interest of the patient must come first. In general, inducement rules must ensure that the prescriber or dispenser exhibits rational prescribing or delivery behaviour, and is not influenced in a manner deemed undesirable.

Inducement within the Erasmus MC
Employees are always responsible for balancing interests in the event of a possible inducement. When balancing interests, the (scientific) independence, reliability, care and impartiality of the employee and, by extension, the Erasmus MC, must always prevail. Even the appearance of dependence, unreliability, carelessness or bias should be avoided.

Balancing interests is not always easy. If in doubt, employees can present the case to their supervisor. In this context, their program director acts as a supervisor for students. In addition, if employees or managers have any doubt, they can submit the case to a confidential adviser for advice.

Starting point for company inducements
The starting point within the Erasmus MC with regard to dealing with companies can be described as follows: society must be able to count on the sound choices of the Erasmus MC when it comes to knowledge transfer and scientific research activities. The importance of the Erasmus MC’s public tasks must be paramount. In practice, this means that no concessions can be made with regard to the quality, reliability, independence and accuracy of scientific research and knowledge transfer.

Situations in which companies might demonstrate inducement
The following situations can be distinguished:

- Companies might offer gifts to employees of the Erasmus MC;
- Companies might invite employees of the Erasmus MC to accept hospitality during meetings (types of hospitality could include meals, accommodation costs, etc.);
- Companies might offer employees of the Erasmus MC sponsorship for activities related to scientific research and knowledge transfer;
- Companies might honour services provided by employees of the Erasmus MC;
- Employees of the Erasmus MC might be involved in giving assignments to companies.
Receiving gifts
Receiving gifts in person is permitted, as long as the gift is of limited value and is significant for carrying out work in the field of scientific research and knowledge transfer. No conditions may be attached to the receipt of such a gift.

Employees must realize that the act of giving and receiving gifts can create expectations. A gift can be given as a thank you for cooperation, but it could also be given as inducement for a service or assignment. An employee must be consciously aware of the possibility of these situations and abide by the following rules:

- Do not accept gifts that are valued at more than € 50 at a time, with a maximum of € 150 per year;
- Report all gifts with an estimated value of more than € 10 to your manager;
- Share gifts with colleagues whenever possible.

Accepting invitations and hospitality offered during meetings
Invitations, regardless of whether the costs are borne by the company or not, can never be accepted in exchange for compensation. Accepting an invitation must serve a functional purpose, and must be done in consultation with the department head / supervisor.

Accepting hospitality during meetings means accepting reimbursement or accepting travel, accommodation or registration costs, meals, and so on, from companies during meetings.

Hospitality may only be accepted after approval from the department head / supervisor, and when it meets at least the following conditions:

- The hospitality must remain limited to a suitable location, and be secondary to the main purpose of the meeting;
- Attending the substantive part of the meeting is necessary, so that the Erasmus MC employee participates in a way that is meaningful and in line with (future) professional activities;
- Hospitality costs that are reimbursed or not charged by an entrepreneur or third party may not exceed € 500 at a time or € 1,500 per year;
- A maximum of 50% of hotel and registration costs may be borne by the company for program participants who don’t actively participate;
- Accepting hotel stays for domestic meetings is only permitted if the total travel time by public transport on one day is such that the participant cannot reasonably travel there or back from home;
- Speakers at meetings must be transparent about their ties with entrepreneurs, suppliers or third parties.

Accepting sponsorship of activities
Sponsorship is defined here as:
- Financial support;
- Other support that can be valued by money, such as the supply of (research) material.

Sponsorship is not understood to mean compensation as referred to in the Services to companies section. Sponsoring is only permitted if it is of a non-binding nature: the reliability, independence, impartiality and care of the Erasmus MC’s employees must be guaranteed in all cases.

Financial or other monetary support that can be valued by companies may never be personally or independently accepted by the employee. Acceptance must be done by the person who is authorized to do so in accordance with the Erasmus MC rules of authority. These financial resources must always be added to the department budget. The budget holder has complete freedom with regard to the use of the financial resources related to the activity.

**Services to companies**

When there is an award from a company, the following conditions apply to the performance of work (at the request of the company) that is in line with tasks in the field of scientific research or knowledge transfer:

- If an award is received in the context of scientific research or knowledge transfer, this financial information must be publicly available to mitigate the appearance of a potential conflict of interest;
- The reliability, care and impartiality of the Erasmus MC is the absolute standard when balancing interests. Even the appearance of unreliability, carelessness or bias should be avoided;
- If the work is performed on behalf of – or at the request of – a company, the employee may never accept it independently. To this end, the employee must at all times have explicit permission from the department head / direct manager within the Erasmus MC. Formal acceptance must take place by the person who is authorized to do so in accordance with the Erasmus MC rules of authority;
- Consultancy Agreements between a researcher and their employer on the one hand, and the company on the other, must be concluded according to a procedure that limits conflicts of interest as much as possible, that does justice to the necessary transparency related to that conflict, and that is in line with the guidelines in the UMC’s Collective Labour Agreement for ancillary activities.

**Inducements and academic education & training tasks**

Inducement could potentially lead to activities with and by students, assistants, doctor’s assistants and PhD students. The following principles to prevent conflicts of interest therefore apply:

- During teaching, supervision or training, teachers, supervisors and trainers of medical students, interns, doctor’s assistants, researchers and PhD students may not be guided other than by purely academic motives in the field of education, training and scientific research;
Assignments to medical students, interns, doctor’s assistants, researchers and PhD students must be aimed at and serve the academic development needs of the person involved;

- The teacher, supervisor and / or trainer must exercise transparency towards the student, assistant, doctor’s assistant, researcher and / or PhD student with regard to the personal interest of the teacher, supervisor and / or trainer;

- The student, assistant, doctor’s assistant, researcher or doctoral candidate must publish the results that arise from their work in the context of the training or research that they carry out.

The above principles also apply to all situations in which employees advise, guide and supervise colleagues.

Giving assignments to companies

Employees of the Erasmus MC may not be involved in giving assignments to companies in which they themselves have interests. This prevents unwanted conflicts of interest when it comes to valorization.

Financial Conflicts of Interest (FCOI)

Conflicts of interest occur when an employee, or the department / part of the organization for which they work, has financial or personal ties with other persons or organizations that could possibly influence research or other activities taking place within the Erasmus MC.

Such situations could include accepting so-called ancillary activities such as political, administrative, advisory, shareholder or supervisory positions. The influence of third parties can be large or limited.

Financial interests (such as financial claims, payment for advisorships, shareholder positions, donations and royalties) are sources of conflicts of interest that are easy to identify. There is a high chance that such interest can undermine scientific independence. However, a conflict of interest can also exist without the employee being aware of it.

Conflicts of interest are often associated with the interests of (pharmaceutical) companies, but they can also arise from personal relationships. Sponsored research by the government or other investors can also give rise to conflicts of interest.

The Erasmus MC’s general policy in this area complies with the rules and guidelines as described in the Public Health Service’s regulation CFR50 Subpart F "Promoting objectivity in research" and reads as follows:

a. Article 9.3 Ancillary activities from the CAO UMC 2018-2020
b. The Erasmus MC participation scheme provides a framework of possibilities that guarantees a balanced weighing of interests between academic and commercial priorities when making decisions regarding shareholdings by employees of the Erasmus MC.

c. Transparency. The independent position of individual employees and the reputation of the Erasmus MC as a whole is guaranteed through rules such as
the obligation of all employees to report to their manager any external appointment that may lead to a (financial) conflict of interest. Employees must also report on the bodies / organizations that contribute to research. Every 12 months, the Board of Directors asks professors and associate professors for an overview of external activities (including finances). This data is published on the Erasmus MC website. Department heads and other managers are responsible for the timely delivery of this data.

d. Openness. Transparency itself does not prevent the creation of a conflict of interest. Openness and discussions during the annual interview can help (financial) relationships to become more visible and talked about.

Erasmus MC researchers and dealing with the media
Media attention for scientific (bio) medical research is important. Researchers can inform society about scientific developments and show how public funds are spent. Positive reporting can also facilitate fundraising and give research institutions a reputation for solid expertise. However, there are also risks. It can be difficult to present researcher messages in a nuanced way. This can result in a misleading public view of research results and their application in health care. Commercial and political interests can also create undesirable influence. Careful and responsible action is therefore required.

Rules and guidelines apply to contacts with journalists within the Erasmus MC. The most important rule is: all press contacts go through the press officers. Never speak to the media without prior consultation with the press officer. Only authorized employees or designated experts may speak on behalf of the Erasmus MC. If an employee speaks about the Erasmus MC in a personal capacity, they must identify themselves as an employee and say that they are not speaking on behalf of the Erasmus MC.

When it comes to social media, you are permitted to use your personal title. However, remember that you are the organization’s calling card. Employees can be held legally responsible for what they say and do online.

2.9 Intellectual property

Ownership and protection of research results
As an employer, the Erasmus MC is designated by Dutch Copyright Law as the economic owner of all works and new inventions by a researcher. This means that the researcher may not monetize these products, or use them for purposes other than the performance of their position at the Erasmus MC, without the permission of the Erasmus MC. A scientific researcher falls under legislation in the field of intellectual property with regard to the results of their research. For example: copyrights on publications and software; patent law on new products or methods.

Intellectual property at the Erasmus MC
The Erasmus MC has an active policy when it comes to the protection and valorization of knowledge. The scientific departments are supported in this area by business developers and lawyers from the Technology Transfer Office (TTO).
Some important principles of the Erasmus MC’s policy when it comes to the valorization of research results are:

a. The financial benefits of research that is (partially) funded by community funds must be returned to the Erasmus MC in a manner proportionate to supporting further research;
b. The Dutch Patent Act stipulates that the intellectual property (such as an invention) of people employed by a university, college or research institution is the property of the university, college or research institution involved;
c. Scientific freedom, and in particular the possibility of publishing and further using all results for scientific research, must be guaranteed at all times.

There are different forms of legal protection:

**Patents**
Patent law offers protection for new products or methods. The patent holder has the exclusive right to market the invention for a period of 20 years.
To ensure that an invention retains its commercial potential, it is important that the invention is protected in time, through the timely application for patent or design protection. The adequate protection of inventions stimulates the transfer of knowledge to business and therefore to society. To be eligible for patent protection, an invention must meet the following requirements:

**Novelty:**
The product or method may not be publicly known anywhere else in the world before the date of filing the patent application, not even by the inventor themselves (for example through inclusion in a dissertation, a public business discussion or a presentation at a trade fair).

**Inventiveness:**
The inventiveness of an invention is assessed by the relevant authorities. In short, an invention should not be obvious to a person skilled in that area.

**Industrial applicability:**
The invention must be a technically-demonstrable, functioning product or production process. Services, natural science theories, calculation methods, medical procedures, or ideas without concrete effect and aesthetic design cannot be protected by a patent. Other forms of protection may apply, such as copyright, design law or trademark law.

**Patent policy and financial aspects at the Erasmus MC**
At the Erasmus MC, knowledge exploitation is a means of carrying out one of our core tasks: making the knowledge we develop available to society. Industry will not want to invest in the further development of inventions that are not protected. The Erasmus MC applies for patent protection for patentable knowledge that is expected to be of interest to the business community. Subsequently, TTO, in collaboration with the relevant department, seeks a market player that is able to bring the invention to the market.
Copyright
Anybody who creates a literary, scientific or artistic work can immediately claim copyright protection. Examples of works that are subject to copyright protection include: texts, software, artworks, films, photos, scale models, and construction works. The copyright notice ‘©’ (in combination with the name of the rights-holder and the year of first publication) can be used to state that there is a copyright on a certain work. The use of this sign is not an obligation in the Netherlands. There are no costs associated with copyright, and protection is based on the Berne Convention almost everywhere in the world.

Copyright at the Erasmus MC
According to Dutch Copyright Law, copyrights on works performed by the employer belong to the employer. An exception to this rule for scientific work currently applies at the Erasmus MC based on case law and literature (the Doctrine of Verkade). Scientific work must be produced freely. The copyright on a scientific article prepared by an independent researcher therefore belongs to the relevant researcher. If more than one researcher works on a research project and publishes results from it, then the copyright is shared. This exception does not apply to research reports, textbooks, software or designs, for which the Erasmus MC owns copyright. This also includes educational materials such as syllabi.

Database law and data control
A database is any collection of items or data that is organized systematically or methodically by the creator, and that is also accessible as such. A database does not necessarily have to be electronic, only text-based, or containing works that are protected by copyright.

A database is not automatically protected by database law. To be able to claim protection based on database law, there must be a substantial investment in its composition and / or maintenance. This is not just an investment in money.

The owner of the database is the institution or person who has compiled it. This does not mean that the individual data becomes the property of this person or institution. The owner of the database can, just like with other intellectual property (IP), license use for a fee. If an external party orders the creation of a database, it may have stipulated that it is the owner of the database.

Databanks at the Erasmus MC
At the Erasmus MC, it is important to guarantee freedom of scientific publication. If a database falling under the definition of database law is mainly established with resources from the Erasmus MC, then the Erasmus MC owns the database.

The Erasmus MC has control over data from research at the Erasmus MC. Case Report Forms (CRFs), lab journals (digital or otherwise) and other written or digitally recorded research findings are the property of the Erasmus MC. Control over the data has been formally placed with the department heads involved. However, different agreements can be made through proper consultation.

The Erasmus MC supports the idea of data sharing. Agreements must be made about the use of research data for both internal and external cooperation.
Inventions in use at the Erasmus MC

Pursuant to the Patents Act, the Erasmus MC – as the employer – owns all patentable inventions. This also applies to inventions that have come about “under the shower” – in other words, inventions that may have been thought of while outside of the Erasmus MC – provided that the invention relates to the work of the Erasmus MC scientist involved. The inventor is entitled to equitable remuneration, and further rules in this regard are laid down in the Patent Policy of the Erasmus MC. All first patent applications (called ‘premier depôts’) submitted for inventions made within the Erasmus MC must be in the name of “Erasmus University Medical Center Rotterdam”. This ensures that the Erasmus MC and the names of the inventors involved become visible in the international patent registers. This also applies to subsidized collaborations and collaborations with industry (see “Inventions in collaborative projects”).

Attribution of inventions

In short, the inventor of a patentable invention is the person who has taken the inventive step. Inventive activity occurs when what has been invented is not obvious to a person skilled in the area. It does not matter how the inventor created the invention. It is therefore irrelevant whether the finding was made by accident or as a result of systematic research. An inventor as described above is not the same as an author of a scientific publication: in most cases there is only one person who has made the substantially inventive contribution and can be listed as an inventor in a patent on that basis.

If there are more inventors, they will of course be mentioned. Determining inventorship when applying for a patent is not optional, and the legal criteria for inventorship must be met. Inventing is not the same as authorship in the publication of a new development. An incorrect listing of inventors, particularly in the US, can lead to the patent being invalid.

Attribution at the Erasmus MC

The inventor within the meaning of patent legislation is entitled to have their name added to the patent application, and ultimately to the patent granted. That is, the inventor can be mentioned as such alongside the owner of the patent: the Erasmus MC.

If employees of the Erasmus MC have contributed to the research project in question without being an inventor within the meaning of the patent legislation, their department head can make further arrangements in the form of a reward or scientific recognition.

Inventions in collaborative projects

Collaborative projects between the business community and the Erasmus MC are common. If such a project results in a new product or process, it is important that the parties make agreements at the outset about the rights to the invention in question. For the knowledge institution, such a project is often part of a broader research program.

To guarantee continuity, IP agreements with cooperative partners must not
impede further investigation. TTO’s lawyers can provide advice about drafting good cooperative contracts with industry, tailored to the specific circumstances of the case.

Patent applications for inventions made by the Erasmus MC researchers during sponsored collaborative projects should, in principle, be in the name of the Erasmus MC. This will ensure that the Erasmus MC as a research institute becomes visible in the official patent registers. Furthermore, it is particularly important for visibility that the scientists involved be mentioned as inventors in the patent applications.

TTO acts as a central ‘desk’ where a scientist can go first with any questions in the areas of intellectual property, contracts and knowledge valorization. All agreements involving rights to research results or intellectual property must be submitted to TTO for advice. Patent applications must always be submitted via TTO; the patent portfolio of the Erasmus MC is managed by TTO.
3. References

**Erasmus MC internet**

<table>
<thead>
<tr>
<th>Ancillary activities</th>
<th><a href="https://www6.erasmusmc.nl/overerasmusmc/in-de-maatschappij/nevenfuncties_hoogleraren/">https://www6.erasmusmc.nl/overerasmusmc/in-de-maatschappij/nevenfuncties_hoogleraren/</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Research Ethics Committee</td>
<td><a href="https://www.erasmusmc.nl/en/patient-care/metc-erasmus-mc">https://www.erasmusmc.nl/en/patient-care/metc-erasmus-mc</a></td>
</tr>
<tr>
<td>Open Access Publishing</td>
<td><a href="https://www6.erasmusmc.nl/medbib/Publiceren/OA/?lang=en">https://www6.erasmusmc.nl/medbib/Publiceren/OA/?lang=en</a></td>
</tr>
<tr>
<td>Referentiecheck</td>
<td><a href="https://www.erasmusmc.nl/medbib/Publiceren/6030993/?lang=en">https://www.erasmusmc.nl/medbib/Publiceren/6030993/?lang=en</a></td>
</tr>
<tr>
<td>Technology Transfer Office</td>
<td><a href="http://www.erasmusmc.nl/tto/?lang=en">http://www.erasmusmc.nl/tto/?lang=en</a></td>
</tr>
</tbody>
</table>

**Intranet**

<table>
<thead>
<tr>
<th>Centralized facility for animal research and laboratory animals</th>
<th><a href="https://intranet.erasmusmc.nl/edc/introductie/?lang=en">https://intranet.erasmusmc.nl/edc/introductie/?lang=en</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Confidential Counselor Research Integrity</td>
<td><a href="https://intranet.erasmusmc.nl/serviceportal/?product=Wetenschappelijke%20integriteit&amp;view=Link&amp;itemkey=3986855">https://intranet.erasmusmc.nl/serviceportal/?product=Wetenschappelijke%20integriteit&amp;view=Link&amp;itemkey=3986855</a></td>
</tr>
<tr>
<td>Consultation center for Patient Oriented research</td>
<td><a href="https://intranet.erasmusmc.nl/onderzoeksbeleid/advisering/cpo/?lang=en">https://intranet.erasmusmc.nl/onderzoeksbeleid/advisering/cpo/?lang=en</a></td>
</tr>
<tr>
<td>Course in laboratory animal science</td>
<td><a href="https://intranet.erasmusmc.nl/edc/course_las/">https://intranet.erasmusmc.nl/edc/course_las/</a></td>
</tr>
<tr>
<td>Data protection policy</td>
<td><a href="https://intranet.erasmusmc.nl/carefordata/algemeen/beleid-gegevensbescherming/?lang=en">https://intranet.erasmusmc.nl/carefordata/algemeen/beleid-gegevensbescherming/?lang=en</a></td>
</tr>
<tr>
<td>Datamanagement and storage</td>
<td><a href="https://intranet.erasmusmc.nl/onderzoeksbeleid/researchfac/datamanagementtopslag/?lang=en">https://intranet.erasmusmc.nl/onderzoeksbeleid/researchfac/datamanagementtopslag/?lang=en</a></td>
</tr>
<tr>
<td>Erasmus MC Central Biobank</td>
<td><a href="https://intranet.erasmusmc.nl/eread/projecteneninitiatievenrenneaserviceplatforms/centralebiobank/?lang=en">https://intranet.erasmusmc.nl/eread/projecteneninitiatievenrenneaserviceplatforms/centralebiobank/?lang=en</a></td>
</tr>
<tr>
<td>Erasmus MC Participation Regulation</td>
<td><a href="https://intranet.erasmusmc.nl/tto/oursops/5977963/?lang=en&amp;view=active&amp;type=pdf">https://intranet.erasmusmc.nl/tto/oursops/5977963/?lang=en&amp;view=active&amp;type=pdf</a></td>
</tr>
<tr>
<td>Financial Conflict of Interest Policy</td>
<td><a href="https://intranet.erasmusmc.nl/tto/oursops/5070200/?lang=en&amp;view=active&amp;type=pdf">https://intranet.erasmusmc.nl/tto/oursops/5070200/?lang=en&amp;view=active&amp;type=pdf</a></td>
</tr>
<tr>
<td>Information security</td>
<td><a href="https://intranet.erasmusmc.nl/carefordata/informatiebeveiliging/?lang=en">https://intranet.erasmusmc.nl/carefordata/informatiebeveiliging/?lang=en</a></td>
</tr>
<tr>
<td>Management Development</td>
<td><a href="https://intranet.erasmusmc.nl/personeelsplein/mijn-ontwikkeling/MD/">https://intranet.erasmusmc.nl/personeelsplein/mijn-ontwikkeling/MD/</a></td>
</tr>
<tr>
<td>Policy Measures Human related research</td>
<td><a href="https://intranet.erasmusmc.nl/onderzoeksbeleid/advisering/nietwmo/">https://intranet.erasmusmc.nl/onderzoeksbeleid/advisering/nietwmo/</a></td>
</tr>
<tr>
<td>Scientific Integrity Complaints Procedure</td>
<td><a href="https://intranet.erasmusmc.nl/psyc-cs/2624324/2624343/wi-complaints-procedure">https://intranet.erasmusmc.nl/psyc-cs/2624324/2624343/wi-complaints-procedure</a></td>
</tr>
<tr>
<td>Technology Transfer Office</td>
<td><a href="https://intranet.erasmusmc.nl/tto/?lang=en">https://intranet.erasmusmc.nl/tto/?lang=en</a></td>
</tr>
</tbody>
</table>

**KMS**

Brochure Integrity is part of the Erasmus MC
https://kms.erasmusmc.nl/iDocument/Viewers/Frameworks/View Document.aspx?documentid=56b2c0e8-f9e7-4ef8-af16-906e8df11f13&customcss=&HyperlinkID=c5e244fd-4919-47e9-ab7e-e9ff83a24d34

Conflict Resolution Directive
https://kms.erasmusmc.nl/iDocument/Viewers/Frameworks/View Document.aspx?documentid=bbded0bb-fb06-4509-b620-d6ca15b9d518&customcss=&HyperlinkID=b91b45ff-932b-4f5d-bc8c-255aabf2965c

Erasmus MC Central Biobank Regulation

Explaination of ancillary activities, inducements and financial conflicts of interest
https://kms.erasmusmc.nl/iDocument/Viewers/Frameworks/View Document.aspx?documentid=738f38e2-0e74-441a-8551-675a117a25f3&customcss=&HyperlinkID=2d7c4be4-d2e0-4870-8e5f-b3d550cb968e

Media protocol

Media protocol, short version
https://kms.erasmusmc.nl/iDocument/Viewers/Frameworks/View Document.aspx?documentid=704c643a-78a0-4267-b5ca-afe6fe5ca499&customcss=&HyperlinkID=76bd7024-44e4-bacd-157164014646

Whistleblower procedure
https://kms.erasmusmc.nl/iDocument/Viewers/Frameworks/View Document.aspx?documentid=b55a85e9-f9b4-415f-8451-0ab99131977d&customcss=&HyperlinkID=46f45924-6c7f-4c99-919f-5a92797ffbd

Laws

Copyright Law
https://wetten.overheid.nl/BWBR0001886/2018-10-11

Decree on GMO
https://wetten.overheid.nl/BWBR0035090/2018-11-01

Embryo Act
http://wetten.overheid.nl/BWBR0013797/2018-08-01

Experiments on animals Act

Inducement Guideline Medicines Act
https://wetten.overheid.nl/BWBR0040672/2018-04-01

Nagoya Protocol Implementation Act
https://wetten.overheid.nl/BWBR0037150/2019-01-01

Regulations on GMO
http://wetten.overheid.nl/BWBR0035072

CCMCO

Central Committee on Research Involving Human Subjects
https://english.ccmo.nl/
Code of conduct relating to expressions of objection by minors participating in medical research

Code of conduct relating to the expression of objection by incapacitated (psycho)geriatric patients in the context of the WMO

Code of conduct relating to the expression of objection by people with mental disabilities in the context of the WMO

KNAW

Netherlands Board on Research Integrity

Research Integrity
https://www.knaw.nl/en/topics/ethiek/wetenschappelijke-integriteit/overzicht

Responsible research data management and the prevention of scientific misconduct

NFU

Ancillary activities in the CAO UMC

Company Inducement Guideline

Quality assurance for human research 2019

Training and exam regulations BROK

VSNU

Ancillary activities regulations

Code of conduct for using personal data in research

National Scientific Integrity Complaints Procedure model
http://vsnu.nl/files/documenten/Domeinen/Onderzoek/Landelijk_Model_Klachtenregeling_Wetenschappelijke_Integriteit_Universiteit_X.pdf

Netherlands Code of Conduct for Research Integrity
### Federa

- **Code of Conduct for Responsible Use**
  

- **Code of Conduct for the Use of Data in Health Research**
  

### National

- **4TU.ResearchData**
  
  [https://researchdata.4tu.nl/home/](https://researchdata.4tu.nl/home/)

- **Biobank BBMRI**
  
  [https://www.bbmri.nl/](https://www.bbmri.nl/)

- **Biobank Lifelines**
  
  [https://www.lifelines.nl/](https://www.lifelines.nl/)

- **Biobank ParelSnoer Instituut**
  
  [https://parelsnoer.org/page/nl/](https://parelsnoer.org/page/nl/)

- **Biobank TraIT**
  
  [https://trait.health-ri.nl/](https://trait.health-ri.nl/)

- **Bureau GGO**
  
  [https://www.ggo-vergunningverlening.nl/](https://www.ggo-vergunningverlening.nl/)

- **CentERdata**
  
  [https://www.centerdata.nl/](https://www.centerdata.nl/)

- **Centrale Commissie Dierproeven**
  
  [https://www.centralecommissiedierproeven.nl/](https://www.centralecommissiedierproeven.nl/)

- **Code of conduct for Biosecurity**
  

- **Code of Conduct Medical Devices**
  
  [https://www.cgr.nl/CGR.nl/media/CGR.nl/Gedragscode/20190107-Dutch_CoC_Pharmaceutical_Advertising-ENG-per-20190701.pdf](https://www.cgr.nl/CGR.nl/media/CGR.nl/Gedragscode/20190107-Dutch_CoC_Pharmaceutical_Advertising-ENG-per-20190701.pdf)

- **Code of Conduct Pharmaceutical Advertising**
  
  [https://www.ggd.nl/nl/juridiek/gedragscodes](https://www.ggd.nl/nl/juridiek/gedragscodes)

- **DANS**
  
  [https://dans.knaw.nl/nl/deponeren](https://dans.knaw.nl/nl/deponeren)

- **Data4lifesciences**
  
  [http://www.data4lifesciences.nl/](http://www.data4lifesciences.nl/)

- **GDPR (AVG in Dutch)**
  

- **HANDS (Handbook for Adequate Natural Data Stewardship)**
  
  [https://data4lifesciences.nl/hands2/data-stewardship/](https://data4lifesciences.nl/hands2/data-stewardship/)

- **Health-RI**
  
  [https://www.health-ri.org/](https://www.health-ri.org/)

- **National Focal Point (NFP) on Access and Benefit-Sharing of the Netherlands**
  
  [https://www.absfocalpoint.nl/en/absfocalpoint.htm](https://www.absfocalpoint.nl/en/absfocalpoint.htm)

- **NRIN**
  
  [https://www.nrin.nl/](https://www.nrin.nl/)

- **RePub**
  
  [https://repub.eur.nl/](https://repub.eur.nl/)

- **SURF**
  
  [http://www.surf.nl/](http://www.surf.nl/)

- **Vereniging Innovatieve Geneesmiddelen**
  
  [https://www.vereniginginnovatiegeeneesmiddelen.nl/klinisch-onderzoek](https://www.vereniginginnovatiegeeneesmiddelen.nl/klinisch-onderzoek)

- **www.trialregister.nl**
  
  [http://www.trialregister.nl/](http://www.trialregister.nl/)
### International

| Access and Benefit-sharing Clearing-house | https://absch.cbd.int/ |
| Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities | http://openaccess.mpg.de/Berlin-Declaration |
| CIOMS Ethical Guidelines | https://cioms.ch/shop/product/international-ethical-guidelines-for-health-related-research-involving-humans/ |
| ClinicalTrials.gov | https://clinicaltrials.gov/ |
| COPE | http://www.publicationethics.org/ |
| CoreTrustSeal | https://www.coretrustseal.org/about/ |
| CRediT | https://casrai.org/credit/ |
| Declaration of Helsinki | https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ |
| EQUATOR | http://www.equator-network.org/ |
| EU Clinical Trials Register | https://www.clinicaltrialsregister.eu/joiningtrial.html |
| FAIR data | https://www.force11.org/group/fairgroup/fairprinciples |
| ISRCTN registry | http://www.isrctn.com/ |
| List of Predatory Publishers | https://predatoryjournals.com/publishers/ |
| WHO International Clinical Trials Platform (ICTRP) | http://www.who.int/ictrp/en/ |